



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/APTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/672,144
Filing Date	September 26, 2003
First Named Inventor	Tamarkin et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	01994-0027(42893-292447)

Sheet 1 of 4

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
JEA		2,768,958		Stewart, et al.	10/30/1956	
		2,785,153		Locke, et al.	03/12/1957	
		3,145,144		Ando, et al.	08/18/1964	
		3,149,036		Woodhour, et al.	09/15/1964	
		3,269,912		Grafe	08/30/1966	
		3,399,263		Strazdins, et al.	08/27/1968	
		3,531,565		Webb, et al.	09/29/1970	
		3,577,523		Stolar, et al.	05/04/1971	
		3,651,211		Gillchriest, et al.	03/21/1972	
		3,819,820		Lorina, et al.	06/25/1974	
		3,919,413		Mebus	11/11/1975	
		3,983,228		Woodhour, et al.	09/28/1976	
		4,016,252		Relyveld	04/05/1977	
		4,053,587		Davidson, et al.	10/11/1977	
		4,069,313		Woodhour, et al.	01/17/1978	
		4,177,263		Rosenberg, et al.	12/04/1979	
		4,196,185		Focella, et al.	04/01/1980	
		4,197,237		Leute, et al.	04/08/1980	
		4,197,286		Rao	04/08/1980	
		4,213,964		Buckler	07/22/1980	
		4,215,036		Malley	07/29/1980	
		4,218,436		Fitzpatrick	08/19/1980	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
JEA		WO	91/02078		Peptide Technology Ltd	02/21/1991		
		EP	0 269 408		Genentech, Inc.	11/24/1987		
		FR	2 334 366		A.N.V.A.R.	07/08/1977		
		FR	2 533 827		A.N.V.A.R.	04/06/1984		
		UK	981,242		The Wellcome Foundation Limited	01/20/1965		
		EP	0 044 722		Board of Trustees of the Leland Stanford Junior Univ.	01/27/1982		
		EP	0 179 483		The Juridical Foundation	04/30/1986		
		EP	0 667 398 A2		Kyoto Dai-ichi Kagaku Co., Ltd.	8-16-1995		

Examiner
SignatureDate
Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/672,144
Filing Date	September 26, 2003
First Named Inventor	Tamarkin et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	01994-0027(42893-292447)

Sheet 2 of 4

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/JEA/		4,329,281		Christenson, et al.	05/11/1982	
		4,330,530		Baker	05/18/1982	
		4,332,787		Homcy, et al.	06/01/1982	
		4,339,437		Rosenberg, et al.	07/13/1982	
		4,346,074		Gilmour, et al.	08/24/1982	
		4,487,780		Scheinberg	12/11/1984	
		4,578,270		Csizer, et al.	03/25/1986	
		4,594,325		Lundak	06/10/1986	
		4,608,252		Khanna, et al.	08/26/1986	
		4,624,921		Larrick, et al.	11/25/1986	
		4,624,923		Margel	11/25/1986	
		4,639,336		Jouquey, et al.	01/27/1987	
		4,657,763		Finkelstein	04/14/1987	
		4,693,975		Kozbor, et al.	09/15/1987	
		4,720,459		Winkelhake	01/19/1988	
		4,740,589		Moreno	04/26/1988	
		4,744,760		Molday	05/17/1988	
		4,753,873		Beltz, et al.	06/28/1988	
		4,812,556		Vahlne, et al.	03/14/1989	
		4,880,750		Francoeur	11/14/1989	
		4,906,564		Lyon, et al.	03/06/1990	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/JEA/		EP	0 156 242		Ohtomo et al.	10/02/1985		
		WO	94/21288		Assay Research, Inc.	09/29/1994		
		WO	96/04313		Immunomedics, Inc.	02/15/1996		

Examiner
SignatureDate
Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/672,144
		Filing Date	September 26, 2003
		First Named Inventor	Tamarkin et al.
		Group Art Unit	1616
		Examiner Name	
Sheet 4	of 4	Attorney Docket Number	01994-0027(42893-292447)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/JEA/		Balkwill, et al., "The Cytokine Network," <i>Immun. Today</i> , Vol. 10, No. 9, pp. 299-304 (1989)	
		Coulombe et al., "Cytochemical Demonstration of Increased Phospholipid Content in Cell Membranes in Chloropheniramine-induced Phospholipidosis," <i>The Journal of Histochemistry and Cytochemistry</i> , Vol. 37, No. 2, pp. 139-147 (1989)	
		Fraker, et al., "Passive Immunization Against Tumor Necrosis Factor Partially Abrogates Interleukin 2 Toxicity," <i>The Journal of Experimental Medicine</i> , Vol. 170, pp. 1015-1020 (1989)	
		Goldstein, et al., "Cardiovascular Effects of Platelet-Activating Factor," <i>Lipids</i> , Vol. 26, No. 12, pp. 1250-1256 (1991)	
		Goodman & Gilman's, <i>the Pharmacological Basis of Therapeutics</i> , Ninth Edition, McGraw Hill, New York, (1996), Chapter 51, pages 1260-1261, 1293	
		Hashimoto, et al., "Action Site of Circulating Interleukin 1 on the Rabbit Brain," <i>Brain Research</i> , Vol. 540, pp. 217-223 (1991)	
		Hisamatsu et al., "Platelet Activating Factor Induced Respiratory Mucosal Damage", <i>Lipids</i> , Vol. 26, No. 12, pp. 1287-1291 (1991)	
		Hopkins et al., "Early Events Following the Binding Epidermal Growth Factor to Surface Receptors on Ovarian Granulosa Cells", <i>European Journal of Cell Biology</i> , Vol. 24, pp. 259-265 (1981)	
		Kang et al., "Ultrastructural and Immunocytochemical Study of the Uptake and Distribution of Bacterial Lipopolysaccharide in Human Monocytes," <i>Journal of Leukocyte Biology</i> , Vol. 48, pp. 316-332 (1990)	
		Kirchner et al., "The Development of Neutralizing Antibodies in a Patient Receiving Subcutaneous Recombinant and Natural Interleukin-2", <i>Cancer</i> , Vol. 67, pp. 1862-1864 (1991)	
		Lanzavecchia, "Identifying Strategies for Immune Interventions," <i>Science</i> , Vol. 260, pp. 937-944 (1993)	
		Morris et al., "Validation of the Biotinyl Ligand-Avidin-Gold Technique", <i>The Journal of Histochemistry and Cytochemistry</i> , Vol. 40, No. 5, pp. 711-721 (1992)	
		Ohmann et al., "Expression of Tumor Necrosis Factor- α Receptors on Bovine Macrophages, Lymphocytes and Polymorphonuclear Leukocytes, Internalization of Receptor-Bound Ligand, and Some Functional Effects," <i>Lymphokine Research</i> , Vol. 9, No. 1, pp. 43-58 (1990)	
		Paciotti, G.F., et al. "Interleukin-1 Directly Regulates Hormone-Dependent Human Breast Cancer Cell Proliferation In-Vitro," <i>Mol. Endocrinol.</i> , Vol. 2, pp. 459-464 (1988)	
		Paciotti, G.F., et al. "Interleukin-2 Differentially Effects the Proliferation of a Hormone-Dependent and a Hormone-Independent Human Breast Cancer Cell Line in Vitro and In Vivo," <i>Anticancer Research</i> , Vol. 8, pp. 1233-1240 (1988)	
		Paciotti, G.F., et al. "Interleukin-1 α Differentially Synchronizes Estrogen-Dependent and Estrogen-Human Breast Cancer Cells in the G ₀ /G ₁ I Phase of the Cell Cycle," <i>Anticancer Research</i> , Vol. 11, pp. 25-32 (1991)	
		Peters, et al., "Binding and Internalization of Biotinylated Interleukin-2 in Human Lymphocytes, <i>Blood</i> , Vol 76, No. 1, pp. 97-104 (1990)	
		Roitt, et al., "The Cytokine Network" <i>Immunology</i> , Mosby, (Baltimore, MD) 3rd ed., p. 8.15 (1993)	
↓		Tommi, et al., "Production of Anti-Platelet-Activating Factor Antibodies by the Use of Colloidal Gold as Carrier," <i>Jpn. J. Med. Sci. Biol.</i> , Vol. 44, pp. 75-80 (1991)	

Examiner Signature	/Jon Eric Angell/	Date Considered	10/13/2007
--------------------	-------------------	-----------------	------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.